Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.

Rheumatology (Oxford, England) - 1 Jul 2012

Lazarus Mark N, Turner-Stokes Tabitha, Chavele Konstantia-Maria, Isenberg David A, Ehrenstein Michael R

Abstract excerpt

OBJECTIVES: To correlate the kinetics of B-cell repopulation with relapse after B-cell depletion therapy in SLE patients and address whether variation in relapse rate, B-cell numbers and phenotype are related to anti-dsDNA antibody levels. METHODS: Sixty-one patients with refractory SLE were trea...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Antinuclear
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, CD20

Share to Endopeptidases

Share to Immunity, Cellular

Share to Immunologic Factors

Share to Lupus Erythematosus, Systemic

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 22337941
DOI: 10.1093/rheumatology/ker526
PMCID: PMC3380246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22337941-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.PMID 22337941Read ↗

Single-cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosusSemantic proximity Read ↗

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity.Semantic proximity Read ↗

Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritisSemantic proximity Read ↗

A reservoir of rituximab-resistant splenic memory B cells contributes to relapses after B-cell depletion therapySemantic proximity Read ↗

B Cell Subsets and Cellular Signatures and Disease Relapse in Lupus Nephritis.Semantic proximity Read ↗

Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis.Semantic proximity Read ↗

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.Semantic proximity Read ↗

A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.Semantic proximity Read ↗

Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients.Semantic proximity Read ↗

Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.Semantic proximity Read ↗

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.Semantic proximity Read ↗

The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.